At what level should LDL-cholesterol be reduced for secondary prevention? Rationale and design of the NIH Post-CABG clinical trial

✍ Scribed by L. Campeau; D.B. Hunninghake; J.A. Herd; G. Knatterud; J.L. Probstfield; S. Yusuf; J.S. Forrester; I. Goldenberg; B. Hoogwerf; C. White; M. Domanski; J. Davignon; NIH Post-CABG Clinical Trial Investigators

• Book ID: 118325296
• Publisher: Elsevier Science
• Year: 1994
• Tongue: English
• Weight: 151 KB
• Volume: 109
• Category: Article
• ISSN: 0021-9150
• DOI: 10.1016/0021-9150(94)93625-0